Business Description
Cadrenal Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US1276361086
Description
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 559.67 | |||||
Equity-to-Asset | 0.73 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate | 13.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.31 | |||||
9-Day RSI | 57.06 | |||||
14-Day RSI | 55.65 | |||||
6-1 Month Momentum % | -28.17 | |||||
12-1 Month Momentum % | -41.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.72 | |||||
Quick Ratio | 3.72 | |||||
Cash Ratio | 3.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -78.95 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -104.64 | |||||
ROA % | -91.99 | |||||
ROIC % | -1606.88 | |||||
ROC (Joel Greenblatt) % | -26879.31 | |||||
ROCE % | -104.6 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.97 | |||||
Price-to-Tangible-Book | 1.97 | |||||
EV-to-EBIT | -0.45 | |||||
EV-to-Forward-EBIT | -0.29 | |||||
EV-to-EBITDA | -0.45 | |||||
EV-to-Forward-EBITDA | -0.29 | |||||
EV-to-FCF | -0.6 | |||||
Price-to-Net-Current-Asset-Value | 1.97 | |||||
Price-to-Net-Cash | 2.2 | |||||
Earnings Yield (Greenblatt) % | -222.22 | |||||
FCF Yield % | -59.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CVKD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cadrenal Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -5.55 | ||
Beta | 0 | ||
Volatility % | 184.18 | ||
14-Day RSI | 55.65 | ||
14-Day ATR ($) | 0.843353 | ||
20-Day SMA ($) | 6.744574 | ||
12-1 Month Momentum % | -41.23 | ||
52-Week Range ($) | 5.399999 - 32.549999 | ||
Shares Outstanding (Mil) | 1.07 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cadrenal Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cadrenal Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Cadrenal Therapeutics Inc Frequently Asked Questions
What is Cadrenal Therapeutics Inc(CVKD)'s stock price today?
The current price of CVKD is $7.36. The 52 week high of CVKD is $32.55 and 52 week low is $5.40.
When is next earnings date of Cadrenal Therapeutics Inc(CVKD)?
The next earnings date of Cadrenal Therapeutics Inc(CVKD) is .
Does Cadrenal Therapeutics Inc(CVKD) pay dividends? If so, how much?
Cadrenal Therapeutics Inc(CVKD) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |